Cargando…
Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7)
Local renin-angiotensin systems exist in various malignant tumor tissues; this suggests that the main effector peptide, angiotensin II, could act as a key factor in tumor growth. The underlying mechanisms for the anti-angiogenic effect of angiotensin II type 1 receptor blockers need to be further ev...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899087/ https://www.ncbi.nlm.nih.gov/pubmed/24465768 http://dx.doi.org/10.1371/journal.pone.0085891 |
_version_ | 1782300520206041088 |
---|---|
author | Abd-Alhaseeb, Mohammad M. Zaitone, Sawsan A. Abou-El-Ela, Soad H. Moustafa, Yasser M. |
author_facet | Abd-Alhaseeb, Mohammad M. Zaitone, Sawsan A. Abou-El-Ela, Soad H. Moustafa, Yasser M. |
author_sort | Abd-Alhaseeb, Mohammad M. |
collection | PubMed |
description | Local renin-angiotensin systems exist in various malignant tumor tissues; this suggests that the main effector peptide, angiotensin II, could act as a key factor in tumor growth. The underlying mechanisms for the anti-angiogenic effect of angiotensin II type 1 receptor blockers need to be further evaluated. The present study was carried out to investigate the anti-angiogenic effect of olmesartan alone or in combination with sorafenib, an angiotensin (1–7) agonist or an angiotensin (1–7) antagonist in Ehrlich's ascites carcinoma-bearing mice. The tumor was induced by intradermal injection of Ehrlich's ascites carcinoma cells into mice. Tumor discs were used to evaluate the microvessel density; the serum levels of vascular endothelial growth factor (VEGF) and serum insulin-like growth factor I (IGF-I); and their intratumoral receptors, VEGF receptor-2 and IGF-I receptor, respectively. All parameters were determined following the treatment course, which lasted for 21 days post-inoculation. Monotherapy with olmesartan and its combination with sorafenib resulted in a significant reduction in microvessel density and serum levels of VEGF and IGF-I, as well as their intratumoral receptors. In addition, the combination of olmesartan (30 mg/kg) with an angiotensin (1–7) agonist reduced the microvessel density, IGF-I serum levels and the levels of its intratumoral receptor. In conclusion, olmesartan reduced the levels of the angiogenesis markers IGF-I and VEGF and down-regulated the intratumoral expression of their receptors in a dose-dependent manner, and these effects were dependent on the angiotensin (1–7) receptor. These results suggest that olmesartan is a promising adjuvant to sorafenib in the treatment of cancer. |
format | Online Article Text |
id | pubmed-3899087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38990872014-01-24 Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7) Abd-Alhaseeb, Mohammad M. Zaitone, Sawsan A. Abou-El-Ela, Soad H. Moustafa, Yasser M. PLoS One Research Article Local renin-angiotensin systems exist in various malignant tumor tissues; this suggests that the main effector peptide, angiotensin II, could act as a key factor in tumor growth. The underlying mechanisms for the anti-angiogenic effect of angiotensin II type 1 receptor blockers need to be further evaluated. The present study was carried out to investigate the anti-angiogenic effect of olmesartan alone or in combination with sorafenib, an angiotensin (1–7) agonist or an angiotensin (1–7) antagonist in Ehrlich's ascites carcinoma-bearing mice. The tumor was induced by intradermal injection of Ehrlich's ascites carcinoma cells into mice. Tumor discs were used to evaluate the microvessel density; the serum levels of vascular endothelial growth factor (VEGF) and serum insulin-like growth factor I (IGF-I); and their intratumoral receptors, VEGF receptor-2 and IGF-I receptor, respectively. All parameters were determined following the treatment course, which lasted for 21 days post-inoculation. Monotherapy with olmesartan and its combination with sorafenib resulted in a significant reduction in microvessel density and serum levels of VEGF and IGF-I, as well as their intratumoral receptors. In addition, the combination of olmesartan (30 mg/kg) with an angiotensin (1–7) agonist reduced the microvessel density, IGF-I serum levels and the levels of its intratumoral receptor. In conclusion, olmesartan reduced the levels of the angiogenesis markers IGF-I and VEGF and down-regulated the intratumoral expression of their receptors in a dose-dependent manner, and these effects were dependent on the angiotensin (1–7) receptor. These results suggest that olmesartan is a promising adjuvant to sorafenib in the treatment of cancer. Public Library of Science 2014-01-22 /pmc/articles/PMC3899087/ /pubmed/24465768 http://dx.doi.org/10.1371/journal.pone.0085891 Text en © 2014 Abd-Alhaseeb et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Abd-Alhaseeb, Mohammad M. Zaitone, Sawsan A. Abou-El-Ela, Soad H. Moustafa, Yasser M. Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7) |
title | Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7) |
title_full | Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7) |
title_fullStr | Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7) |
title_full_unstemmed | Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7) |
title_short | Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7) |
title_sort | olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing ehrlich's ascites carcinoma: role of angiotensin (1–7) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899087/ https://www.ncbi.nlm.nih.gov/pubmed/24465768 http://dx.doi.org/10.1371/journal.pone.0085891 |
work_keys_str_mv | AT abdalhaseebmohammadm olmesartanpotentiatestheantiangiogeniceffectofsorafenibinmicebearingehrlichsascitescarcinomaroleofangiotensin17 AT zaitonesawsana olmesartanpotentiatestheantiangiogeniceffectofsorafenibinmicebearingehrlichsascitescarcinomaroleofangiotensin17 AT abouelelasoadh olmesartanpotentiatestheantiangiogeniceffectofsorafenibinmicebearingehrlichsascitescarcinomaroleofangiotensin17 AT moustafayasserm olmesartanpotentiatestheantiangiogeniceffectofsorafenibinmicebearingehrlichsascitescarcinomaroleofangiotensin17 |